Compound Physician required WADA prohibited

KPV

Tripeptide derived from alpha-MSH, explored for inflammation and gut healing — low risk, minimal human data.

The story

KPV is not a designed drug. It is the last three amino acids of a hormone, kept after the rest was discarded.

The parent hormone is α-melanocyte-stimulating hormone, a thirteen-residue peptide cleaved from pro-opiomelanocortin with the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (Al-Obeidi et al., J Med Chem 1989). Its pigmentary activity had been known since the 1950s; what changed the story was work at the University of Texas Southwestern Medical Center in Dallas, where James M. Lipton and Anna Catania spent the late 1980s and the 1990s documenting that α-MSH is also a potent endogenous antipyretic and anti-inflammatory agent. The pivotal reduction came in 1989, when Michael E. Hiltz and Lipton reported that the COOH-terminal fragment alone — residues 11 to 13, lysine-proline-valine — retained the anti-inflammatory activity of the whole hormone (FASEB J 1989, DOI 10.1096/fasebj.3.11.2550304; PMID 2550304). A companion paper the following year showed α-MSH(11–13) inhibiting acute inflammation and contact sensitivity in mice (Peptides 1990), and a 1992 study established the specificity of the effect: the tripeptide blocked inflammation induced by IL-1β, IL-6, TNF-α and endogenous pyrogen, but not inflammation induced by LTB4, PAF or IL-8 (Cytokine 1992).

The reason that fragment mattered is structural. α-MSH's melanotropic "message sequence" — the part that binds melanocortin receptors and drives pigmentation — is His-Phe-Arg-Trp at residues 6 to 9, and KPV does not contain it. Anti-inflammatory and pigmentary activity had been separated onto different ends of the same molecule, and the anti-inflammatory end could be made as a three-residue peptide. Subsequent pharmacology reinforced the separation and deepened the mystery: KPV produced no cAMP elevation in human keratinocytes, unlike α-MSH acting through MC1R (Elliott et al. 2004); Schiöth's group described "strong antiinflammatory activity without known cellular target" (2006); and FDA noted in 2026 that across studies "KPV was unable to displace radiolabeled α-MSH binding" (FDA, 2026). Thirty-seven years after the founding paper, FDA still records that "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown."

The second act is gastrointestinal, and it belongs to two groups. In 2008 a Münster team led by Klaus Kannengiesser, Christian Maaser and Andreas Lügering reported that KPV reduced inflammation in two mouse colitis models and — critically — still worked in mice carrying a non-functional melanocortin-1 receptor, confirming the effect was at least partly MC1R-independent (Inflamm Bowel Dis 2008). The same year, Guillaume Dalmasso, Hang Thi Thu Nguyen, Shanthi V. Sitaraman and Didier Merlin at Emory University published the mechanistic answer that has organised the field since: KPV enters intestinal epithelial and immune cells through PepT1, the di/tripeptide transporter that is normally confined to the small intestine but is induced in the colon during inflammatory bowel disease (Gastroenterology 2008). A transporter that appears only where the disease is provided a plausible targeting mechanism, and the Emory group — later at Georgia State University's Institute for Biomedical Sciences — spent the following decade building delivery systems around it: colon-targeted nanoparticles in a polysaccharide hydrogel (Laroui et al., Gastroenterology 2010), then orally administered hyaluronic-acid-functionalised nanoparticles (Xiao, Viennois, Merlin et al., Mol Ther 2017).

That work never reached a human trial. What reached the public instead was the peptide itself. FDA's 2026 briefing document records the route plainly: "Internet search results indicate that websites promote KPV as single-API or multiple-API compounded drug products in oral, injectable, topical, and nasal spray formulations," for "inflammatory bowel diseases, colitis, and Crohn's disease" and also for "mast cell activation syndrome, histamine intolerance, recovery from COVID-19, Lyme disease" (FDA, 2026). The same document notes that outsourcing facilities reported no KPV compounding between January 2017 and June 2025, and that the original 503A nomination — filed by Wells Pharmacy Network for a 0.1% topical cream or gel, a nominated formulation strength on a regulatory record rather than any amount ever given to a person — was later withdrawn. KPV nevertheless went before the Pharmacy Compounding Advisory Committee on 23 July 2026 alongside BPC-157, TB-500, MOTS-c, Semax, Epitalon and emideltide, and the committee voted 8–6 with one abstention to recommend it for the 503A Bulks List — against FDA staff's own written recommendation not to add it (AJMC; STAT, 2026-07-23).

  1. 1989 Hiltz & Lipton report that the COOH-terminal fragment of α-MSH — Lys-Pro-Val — retains the parent hormone's anti-inflammatory activity
  2. 1990 α-MSH(11–13) shown to inhibit acute inflammation and contact sensitivity in mice
  3. 1992 Cytokine specificity mapped: the tripeptide blocks IL-1β-, IL-6- and TNF-α-induced inflammation but not LTB4-, PAF- or IL-8-induced inflammation
  4. 2004 KPV shown to produce no cAMP response in human keratinocytes — evidence it does not act through MC1R as α-MSH does
  5. 2008 Kannengiesser et al. (Münster): KPV reduces DSS and CD45RB-transfer colitis in mice, and still works in MC1R-defective mice
  6. 2008 Dalmasso, Nguyen, Sitaraman & Merlin (Emory): KPV enters epithelial and immune cells via PepT1; oral KPV reduces DSS and TNBS colitis in mice
  7. 2010 Laroui et al.: colon-targeted KPV nanoparticles in an alginate–chitosan hydrogel match free-solution efficacy at a 12,000-fold lower concentration in mice — a measure of the carrier's efficiency in one model, not a potency of KPV
  8. 2016 Viennois et al.: PepT1 shown to promote colitis-associated cancer in mice; KPV reduces tumour burden in the same model
  9. 2017 Xiao, Viennois, Merlin et al.: orally administered hyaluronic-acid-functionalised KPV nanoparticles alleviate ulcerative colitis in mice
  10. 2021–2026 A materials-science literature builds KPV into hydrogels, films, microspheres and prodrug conjugates — colitis, oral mucositis, diabetic wounds, vascular calcification; all preclinical
  11. 2026-04-16 Federal Register notice establishes the public docket for the 503A bulk-substance nominations, KPV among them
  12. 2026-07-23 FDA staff recommend against adding KPV to the 503A Bulks List; the Pharmacy Compounding Advisory Committee votes 8–6 with 1 abstention to recommend it anyway. Non-binding
  13. 2026-08-04 Health Affairs analysis reports FDA identified no human clinical studies for KPV, TB-500, MOTS-c or Epitalon, and that more than half of voting members had potential conflicts for each peptide

What it does

A tripeptide fragment of alpha-MSH explored for inflammation and gut healing. A coherent mechanism story, but essentially no human outcome evidence — one of the least human-validated compounds in the category.

A tripeptide fragment of alpha-MSH studied for anti-inflammatory signaling, including modulation of NF-κB activity, in gut and skin inflammation models.

  • inflammation
  • gut healing
  • injury recovery

What the evidence shows

There is no human data of any kind. FDA's July 2026 review states it "did not identify clinical studies in humans assessing pharmacokinetics or pharmacodynamics of KPV (free base) or KPV acetate via any route of administration," and a ClinicalTrials.gov query returns zero registrations in any phase in any country (re-verified 2026-08-29). What does exist is roughly 35 years of rodent and cell-culture work, strongest in mouse colitis, where KPV reduced inflammation across two independent laboratories and two model types. The limitation that matters most to a reader is that the most persuasive of those results were obtained with engineered delivery — colon-targeted nanoparticles, hyaluronic-acid-functionalised nanoparticles in a hydrogel, a prodrug conjugate — which is not the same thing as swallowing free peptide. Free oral KPV did work in mice given it in drinking water (Dalmasso 2008), so the honest statement is that the delivery question is unresolved, not that free KPV does not work.

Overall evidence strength: Very low certainty

  • Dalmasso G, Nguyen HTT, Sitaraman SV, Merlin D et al. (2008) — PepT1-mediated uptake (2008) Preclinical / mechanistic

    Nanomolar KPV switched off two main inflammatory signalling pathways in gut and immune cells, entered through a transporter (PepT1) that appears in the colon only when it is inflamed, and reduced colitis in mice drinking it — all in a dish or a mouse, none of it telling you what a capsule does in a person.

    Source PMID 18061177

  • Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D (2010) — colon-targeted nanoparticles (2010) Preclinical / mechanistic

    Nanoparticles that fall apart only on reaching the colon protected mice from colitis at a peptide concentration 12,000-fold lower than free KPV in solution needed for comparable effect. Read the ratio as a property of the nanoparticle-plus-hydrogel system in this one model, not of KPV: it measures how much more efficiently the carrier delivered the peptide where it was needed, and it does not travel with the molecule into a capsule, a vial or a cream. That the delivery vehicle rather than the peptide alone does much of the work is this dossier's reading of the result, not a conclusion Laroui et al. state; it is the single clearest published number behind it.

    Source PMID 19909746

  • Kannengiesser K, Maaser C, Heidemann J, Lügering A et al. (2008) — two colitis models, MC1R-independent (2008) Preclinical / mechanistic

    KPV-treated mice recovered earlier, regained more weight and had less colonic inflammation in both models, and the effect survived in mice whose melanocortin-1 receptor does not work — the strongest single argument that KPV is a different kind of molecule from the tanning peptides it is related to.

    Source PMID 18092346

  • Xiao B, Xu Z, Viennois E, Merlin D et al. (2017) — orally targeted HA-functionalised nanoparticles (2017) Preclinical / mechanistic

    Wrapped in a targeting nanoparticle and then a hydrogel that survives the stomach, oral KPV both healed the gut lining and lowered TNF-α in mice — and the untargeted nanoparticle system in the same paper worked less well, meaning the effect scales with how well the carrier finds inflamed tissue.

    Source PMID 28143741

  • Viennois E, Ingersoll SA, Ayyadurai S, Merlin D et al. (2016) — PepT1 and colitis-associated cancer (2016) Preclinical / mechanistic

    More PepT1 meant more and larger tumours and worse inflammation; less PepT1 meant fewer — and KPV reduced tumour burden in the same model. It cuts two ways worth holding together: the only published tumour-model data on KPV is favourable, but KPV's own entry route is a transporter that independently drives colitis-associated cancer.

    Source PMID 27458604

  • FDA (2026) — Pharmacy Compounding Advisory Committee briefing document — REGULATORY EVIDENCE REVIEW (2026)

    FDA found no human data, no animal toxicology submitted or published (no acute, repeat-dose, genotoxicity, reproductive or carcinogenicity studies), and no FAERS adverse-event reports, and concluded that "on balance, the physicochemical characterization, information on historical use, lack of any effectiveness and safety information in humans … weigh against their being added to the 503A Bulks List."

    Source

Common misconceptions

“KPV heals leaky gut — that's what the colitis research shows.”

The colitis research is real, replicated across two independent groups and two different mouse models, and genuinely encouraging (Kannengiesser et al. 2008; Dalmasso et al. 2008). What it is not is evidence about swallowing a capsule of free peptide. The distinction is the whole story of this compound. Free oral KPV does work in mice — Dalmasso's group put it in the drinking water and colitis scores improved, and nothing here should be read as saying free KPV does not work. What the field did next is the interesting part: the entire subsequent arc was an attempt to fix what made that impractical. Laroui et al. reported encapsulated KPV matching free-solution efficacy at a concentration 12,000-fold lower (DOI 10.1053/j.gastro.2009.11.003) — a ratio that describes how efficiently the nanoparticle-plus-hydrogel carrier delivered the peptide in one mouse model, not a property of KPV itself, and not a reason to think a small swallowed amount of free peptide will do. Xiao et al. then showed hyaluronic-acid targeting improved on the untargeted nanoparticle system (DOI 10.1016/j.ymthe.2016.11.020). A 2026 paper built an ROS-responsive prodrug conjugate achieving 3.8-fold greater colonic accumulation than free KPV "with enhanced efficacy even at a 20-fold lower dose" (Sci Adv 2026). Three programmes, sixteen years, one shared premise: getting free peptide to an inflamed colon intact and in useful quantity is the hard part. Sourcing note on the strongest point in this file. Two of those three programmes — Laroui 2010 and Xiao 2017 — come from the same laboratory (Merlin, at Emory and later Georgia State); only Cheng 2026 is independent of it. And the conclusion drawn from all three here — that results obtained with engineered carriers do not transfer to swallowing free peptide — is this dossier's own inference over preclinical work, not a claim any of those papers makes. We think it is correct and it is the most useful thing in this file; it is also the strongest-sounding claim in it resting on the thinnest citation footing, and a reader is entitled to both halves. Two things it does not say: that free KPV does not work (it did, in mice, in drinking water), and that the human gap is large. In a person the gap is unmeasured — not small, not large, not measured at all, because no human bioavailability study of free KPV exists by any route. Honest answer: In that literature the product is the peptide plus a delivery system, and none of those systems is what is sold. "Leaky gut" is a further step removed: the models are chemically or immunologically induced colitis with visible mucosal ulceration, not the diffuse permeability syndrome the marketing describes. FDA searched for human data on any KPV formulation and found none (FDA, 2026).

“It's derived from α-MSH, so it will darken your skin like melanotan.”

No — and this is one of the cleanest structure–function distinctions in the peptide space. α-MSH's melanotropic activity resides in the "message sequence" His-Phe-Arg-Trp at residues 6–9. KPV is residues 11–13 and does not contain it. Functionally: KPV produced no cAMP elevation in human keratinocytes, unlike α-MSH acting through MC1R (Elliott et al. 2004); FDA's review records that across studies "KPV was unable to displace radiolabeled α-MSH binding" (FDA, 2026); and KPV's anti-colitic effect persisted in mice engineered to have a non-functional melanocortin-1 receptor (Kannengiesser et al. 2008). Melanotan I (afamelanotide) and melanotan II are α-MSH analogues built around the message sequence and are potent melanocortin-receptor agonists; KPV is a fragment built around the other end of the molecule. KPV is not a tanning peptide. The corollary is less comfortable: because it acts through no characterised melanocortin receptor, FDA states that "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown."

“There's a large body of research behind KPV.”

There are roughly 120 PubMed-indexed records mentioning the tripeptide across 35 years, which sounds substantial until you look at what they are. A large share are materials-science and drug-delivery papers in which KPV serves as a well-behaved anti-inflammatory payload for testing a hydrogel, film, microsphere or nanoparticle — the science under study is the carrier, not the peptide. Human studies: zero, confirmed by FDA's own search and by independent review of the same evidence (FDA, 2026; Health Affairs, 2026). Registered trials: zero.

“It has no reported side effects.”

True and uninformative. FDA searched the FAERS adverse-event database and "did not retrieve any reports," and its literature search "did not identify any cases of adverse events" (FDA, 2026). It also found no acute-toxicity, repeat-dose-toxicity, genotoxicity, developmental/reproductive-toxicity or carcinogenicity studies — none submitted by the nominator and none in the published literature. An empty adverse-event record next to an empty toxicology record and no documented clinical use measures how little anyone has looked, not what would be found. FDA's unresolved concerns are immunogenicity and aggregation: "Aggregation is a risk factor in immunogenicity and for decreased pharmacotherapeutic effect," and both nominated forms lacked microbiological quality-control data. Two further reasons "anti-inflammatory, so harmless" does not follow: KPV's action is selective — it blocked IL-1β-, IL-6- and TNF-α-driven inflammation but not LTB4-, PAF- or IL-8-driven inflammation (Cytokine 1992) — and PepT1, the transporter it depends on, independently promoted tumour number, size and inflammation in a mouse colitis-associated cancer model, though KPV itself reduced tumour burden there (Viennois et al. 2016).

“The FDA approved KPV in July 2026.”

An FDA advisory committee voted 8–6 with one abstention to recommend adding KPV to the section 503A bulk drug substances list, meaning compounding pharmacies could use it as a starting material. That is not drug approval and not even a decision: FDA staff had recommended against adding it and the committee voted the other way; recommendations are non-binding, FDA need not follow them, and nothing changes until notice-and-comment rulemaking concludes (Buchanan Ingersoll & Rooney; AJMC). Health Affairs analysts argue the main practical effect may be reputational rather than legal: "Adding these substances to the 503A Bulks List could give them the unwarranted appearance of regulatory legitimacy" (Health Affairs, 2026). ⚠️ Conflict-of-interest finding — reported, attributed, and single-sourced. The same analysis states that "for each peptide, more than half of the participating voting members had relationships that raised potential conflicts" (Health Affairs, 2026). That is reported here without inference about any individual's motive, and it rests on one outlet with no second source; it carries a ledger row and is in the closing list. A second part of that finding is not carried in this dossier. The same analysis further alleges that the conflict-of-interest waivers federal law requires to be posted or announced were not. That is an assertion that a statutory requirement was breached, resting on a single outlet, with no corroborating report and no FDA record located either way. It does not meet the sourcing bar for a reader-facing claim and has been withdrawn from the body. What stands in its place is the absence: whether waivers were posted or announced for this meeting is not established here. What would settle it — FDA's own meeting materials, or a second independent report.

“KPV cream works for eczema and psoriasis.”

Topical was the original nominated use — a 0.1% cream or gel for "wound healing, inflammatory conditions (psoriasis, eczema, etc.)"; that strength is a regulatory record of what was nominated, not an exposure, since the nomination was withdrawn and no human has been described receiving it. It is also the use case with a specific human-tissue finding against it. FDA records an in-vitro study reporting that KPV "does not permeate through cadaver human skin," noting that low permeability "could limit the systemic toxicity of KPV applied topically" but equally "could also limit the potential effectiveness of KPV as a topical therapeutic agent." Penetration was achieved only by breaching the stratum corneum with iontophoresis or microneedle abrasion — not techniques any consumer product uses (FDA, 2026; assay method in Pawar et al. 2015). The nomination was later withdrawn. ---

Who it's for, who should skip

Experimental only. Status is gray_zone — PCAC-recommended but unlawful pending rulemaking; no standardized human protocol exists. Third-party purity testing essential if pursued at all.

Running it

No dosing protocol is published for this compound — there is no lawful supervised channel for the use this guide covers. What follows is monitoring, expectations, and safety framing only.

Form
injectable

What to expect

  • Onset — Not established in humans by any route. In mice, colitis endpoints (weight regain, histology, myeloperoxidase) improved over the days of a standard DSS or transfer-colitis protocol (Confidence: Preclinical only — DOI 10.1002/ibd.20334)
  • Onset (as marketed) — Vendor and clinic material describes digestive-symptom improvement in "two to three weeks" and food-sensitivity change at "six to eight weeks," and a "die-off" reaction in the first 3–7 days (Confidence: Anecdotal, low confidence — no trial support of any kind; recorded as an example of what is claimed (vendor guide))
  • Plateau — No data in any species. No study has run a dose–response or time–response curve to a plateau (Confidence: No data)
  • Post-cessation — No data in any species. No withdrawal, rebound or durability observation has been published (Confidence: No data)
  • Long-term — No data. FDA identified no repeat-dose toxicity and no carcinogenicity study (Confidence: No data — FDA, 2026)
  • Pharmacokinetics — No human PK study by any route. Half-life, absorption and distribution figures circulating online have no published human source (Confidence: No data — FDA, 2026)

Response signs

Likely working

  • Reduced GI symptoms — urgency, cramping, stool frequency — Anecdotal, low confidence. The mouse-model analogue (reduced colonic inflammation on histology) is real; the human subjective analogue has never been measured · DOI 10.1002/ibd.20334 Anecdotal
  • Reduced skin redness or itch from a topical preparation — Anecdotal, low confidence — and with a specific finding against the premise, since KPV does not permeate intact human skin in vitro · FDA, 2026 Anecdotal
  • General reduction in "inflammation" or histamine-type symptoms — Anecdotal, low confidence. Among the promoted uses FDA documents; no study in any species addresses mast-cell activation or histamine intolerance · FDA, 2026 Anecdotal

Adverse — seek review

  • Any hypersensitivity-type reaction — rash, urticaria, wheeze, facial or throat swelling, hypotension after a dose — Mechanistic concern, not documented. This is FDA's named worry for KPV specifically: immunogenicity, with consequences that can be "life-threatening and catastrophic" · FDA, 2026
  • Injection-site reaction that spreads, warms, or persists — Inference, not documented. No injectable KPV study exists in any species; sterility and microbiological quality were among FDA's uncontested deficiencies in the nomination · FDA, 2026 Inference
  • Worsening or unchanged GI symptoms in someone with diagnosed IBD who has substituted or delayed proven therapy — Inference, not documented — but the most consequential risk in this dossier. FDA-approved therapies exist for the conditions KPV is marketed for; there is no evidence KPV substitutes for any of them · FDA, 2026 Inference
  • Systemic symptoms — fever, malaise — after a dose — Inference, not documented for KPV. Flagged because measured gray-market peptide purity has run as low as 5%: most of a vial may not be the labelled peptide · ECRI & ISMP, 2026 Inference

Common / neutral

  • No perceptible effect at all — Consistent with the record. KPV has no documented acute perceptual signature in any species, and no human pharmacology at all · FDA, 2026
  • A "die-off" or transient worsening in the first days — Anecdotal, low confidence. Described in vendor material; not a documented phenomenon for KPV in any study, and not a recognised pharmacological effect of the molecule · vendor guide Anecdotal

Getting it right

  • Monitoring: There is no efficacy marker to monitor. Nothing has been validated and nothing has been measured in a human. Any monitoring plan for KPV is safety monitoring by default. mitigate side effect
  • Monitoring: Baseline before, not after. With no published pharmacology, a pre-exposure baseline is the only thing that makes a later laboratory change interpretable. mitigate side effect
  • Monitoring: Monitor the underlying condition on its own terms. For diagnosed IBD, the established markers — endoscopic findings, faecal calprotectin, CRP — remain the measure of disease control. None has been measured in relation to KPV, so a change in them cannot be attributed to it. mitigate side effect
  • Monitoring: There is no observed window to reason from. No study in any species followed animals beyond a colitis-model protocol, and no repeat-dose toxicity study exists. Open-ended use sits outside any observation anyone has made. mitigate side effect
  • General safety: Product identity is the leading practical risk, ahead of pharmacology. ECRI and ISMP reported in 2026 that patients using wellness peptides "have no reliable information about whether they are safe or effective," and that gray-market product testing found purity from 5% to 75% with arsenic and lead above toxicity thresholds (ECRI & ISMP, 2026). These figures describe the market, not KPV, and are not attributed to it here. mitigate side effect
  • General safety: Immunogenicity and aggregation are FDA's named concerns, both formulation-dependent: peptides "can be extremely sensitive to product formulation, process, and environmental conditions … which may lead to the aggregation and degradation of peptides," and neither nominated KPV form came with microbiological quality-control data (FDA, 2026). mitigate side effect
  • General safety: Substitution is the risk with a documented cost. FDA-approved therapies exist for the conditions KPV is marketed for. Delaying or replacing proven IBD therapy has well-characterised consequences; KPV's benefit is not characterised at all. mitigate side effect
  • General safety: Pregnancy, breastfeeding and childhood are entirely unstudied. FDA identified no developmental or reproductive toxicity study of any kind. mitigate side effect
  • The physician conversation: What is being treated, and what is the evidence for the treatments I have not tried yet? mitigate side effect
  • The physician conversation: If this is for suspected IBD or persistent GI symptoms, has the diagnosis been established — and is anything being deferred while a peptide is trialled? mitigate side effect
  • The physician conversation: Given that no human has been studied on KPV by any route, what would we watch for, and what would make us stop? mitigate side effect
  • The physician conversation: Do I have a history — autoimmune disease, prior biologic therapy, prior reactions to injected products — that makes an unstudied immunogenicity risk less acceptable in my case? mitigate side effect
  • The physician conversation: What is the regulatory status this week? The July 2026 vote changed nothing legally; has rulemaking concluded? mitigate side effect
  • The physician conversation: If I am an athlete or in military service, what does mean for me specifically? mitigate side effect
  • The physician conversation: If I have already taken something labelled KPV, how do I get anything I noticed recorded rather than lost? mitigate side effect

Safety

  • low reported risk, but that reflects limited human use rather than established safety; unregulated sourcing caveats apply

Stacking & alternatives

  • Alternative to BPC-157 — The closest functional neighbour: same gut/anti-inflammatory positioning, same advisory-committee day, same absence of controlled human efficacy data — but a different molecule and mechanism (VEGFR2/Akt–eNOS versus an unidentified target reached via PepT1). BPC-157 has three published human pilot studies; KPV has zero (FDA, 2026)
  • Complements BPC-157 — The dominant marketed pairing for gut claims. No study in any species has tested the combination
  • Alternative to Thymosin Alpha-1 — Also an immune-modulating peptide, but with registered human trials and approvals in several countries, and a different intent (immune stimulation rather than local anti-inflammatory action)

Access & cost

Legally unsettled. Access, where it exists at all, runs through a physician — not a consumer purchase. See the status note above.

No lawful channel to price. As of 2026-08-28 there is no lawful US route to obtain KPV for human use — no approval, no USP–NF monograph, no 503A Category 1 listing — so no legitimate compounding-pharmacy, telehealth or brand price exists to report (BSCG; FDA, 2026). A market nonetheless exists outside that channel: FDA's own review records that "internet search results indicate that websites promote KPV as single-API or multiple-API compounded drug products in oral, injectable, topical, and nasal spray formulations" (FDA, 2026). no gray-market price figure for KPV met the sourcing bar of journalist-reported rather than seller-obtained. The omission is deliberate.) ---

Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.